Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

  • A study by a team at Genentech Inc. proposes a new mechanism for Alzheimer's disease pathogenesis by outlining a process that could be an early step in the neurodegenerative disorder. The work also identifies a trio of new AD targets, which the company is pursuing with preclinical programs. The study suggests that the previously ignored amino-terminal portion of amyloid precursor protein (APP), called N-APP, might be the main culprit behind AD. APP is a transmembrane protein that gives rise to N-APP and the much more commonly known -amyloid (A), a fragment that forms the amyloid fibers and plaques that are hallmarks of AD, although the precise role of those fibers and plaques in disease pathology is unclear.

One Response to “links for 2009-05-12”

Comments are closed.

error: Content is protected !!